Chr del(17p)
Chr del(17p)
|
Chronic Lymphocytic Leukemia
CLL
|
venetoclax + obinutuzumab
|
Chr del(17p)
Chr del(17p)
|
Chronic Lymphocytic Leukemia
CLL
|
|
Chr del(17p)
Chr del(17p)
|
Chronic Lymphocytic Leukemia
CLL
|
|
Chr del(17p)
Chr del(17p)
|
Chronic Lymphocytic Leukemia
CLL
|
|
Chr del(17p)
Chr del(17p)
|
Chronic Lymphocytic Leukemia
CLL
|
|
Chr del(17p)
Chr del(17p)
|
Chronic Lymphocytic Leukemia
CLL
|
|
Chr del(17p)
Chr del(17p)
|
Chronic Lymphocytic Leukemia
CLL
|
ofatumumab
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Chronic Lymphocytic Leukemia
CLL
|
rituximab
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Chronic Lymphocytic Leukemia
CLL
|
venetoclax + rituximab
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
zanubrutinib
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Chronic Lymphocytic Leukemia
CLL
|
zanubrutinib
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
rituximab
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
ibrutinib
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Chronic Lymphocytic Leukemia
CLL
|
idelalisib
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
ofatumumab
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
idelalisib
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
venetoclax
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
rituximab + idelalisib
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
duvelisib
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
venetoclax + rituximab
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
obinutuzumab
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
alemtuzumab
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
rituximab + alemtuzumab
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
venetoclax + obinutuzumab
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
acalabrutinib
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
obinutuzumab + acalabrutinib
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Chronic Lymphocytic Leukemia
CLL
|
lenalidomide
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
lenalidomide
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
rituximab + lenalidomide
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Chronic Lymphocytic Leukemia
CLL
|
rituximab + lenalidomide
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Chronic Lymphocytic Leukemia
CLL
|
alemtuzumab
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Chronic Lymphocytic Leukemia
CLL
|
pembrolizumab
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Chronic Lymphocytic Leukemia
CLL
|
nivolumab
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Chronic Lymphocytic Leukemia
CLL
|
duvelisib
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Chronic Lymphocytic Leukemia
CLL
|
obinutuzumab
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Chronic Lymphocytic Leukemia
CLL
|
obinutuzumab + acalabrutinib
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Chronic Lymphocytic Leukemia
CLL
|
rituximab + alemtuzumab
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
pembrolizumab
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
pembrolizumab + ibrutinib
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Multiple Myeloma
Multiple Myeloma
|
bortezomib + selinexor
Sensitive: B - Late Trials
|
Chr del(17p)
Chr del(17p)
|
Multiple Myeloma
Multiple Myeloma
|
DVD
Sensitive: B - Late Trials
|
Chr del(17p)
Chr del(17p)
|
Multiple Myeloma
Multiple Myeloma
|
lenalidomide + elotuzumab
Sensitive: B - Late Trials
|
Chr del(17p)
Chr del(17p)
|
Multiple Myeloma
Multiple Myeloma
|
daratumumab
Sensitive: B - Late Trials
|
Chr del(17p)
Chr del(17p)
|
Chronic Lymphocytic Leukemia
CLL
|
ibrutinib + ublituximab
Sensitive: B - Late Trials
|
Chr del(17p)
Chr del(17p)
|
Chronic Lymphocytic Leukemia
CLL
|
obinutuzumab
Resistant: B - Late Trials
|
Chr del(17p)
Chr del(17p)
|
Multiple Myeloma
Multiple Myeloma
|
Isa-KRd
Sensitive: C2 – Inclusion Criteria
|
Chr del(17p)
Chr del(17p)
|
Non-Hodgkin’s Lymphoma
NHL
|
T-lymphocyte cell therapy
Sensitive: C3 – Early Trials
|
Chr del(17p)
Chr del(17p)
|
Chronic Lymphocytic Leukemia
CLL
|
lenalidomide + tafasitamab
Sensitive: C3 – Early Trials
|
Chr del(17p)
Chr del(17p)
|
Multiple Myeloma
Multiple Myeloma
|
lenalidomide + ixazomib
Sensitive: C3 – Early Trials
|
Chr del(17p)
Chr del(17p)
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
LOXO-305
Sensitive: C3 – Early Trials
|
Chr del(17p)
Chr del(17p)
|
Chronic Lymphocytic Leukemia
CLL
|
LOXO-305
Sensitive: C3 – Early Trials
|
Chr del(17p)
Chr del(17p)
|
Multiple Myeloma
Multiple Myeloma
|
Proteasome inhibitor + Immunomodulator
Resistant: C3 – Early Trials
|
Chr del(17p)
Chr del(17p)
|
Chronic Lymphocytic Leukemia
CLL
|
RP6530
Sensitive: C3 – Early Trials
|
Chr del(17p)
Chr del(17p)
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
ICP-022
Sensitive: C3 – Early Trials
|
Chr del(17p)
Chr del(17p)
|
Chronic Lymphocytic Leukemia
CLL
|
ICP-022
Sensitive: C3 – Early Trials
|
Chr del(17p)
Chr del(17p)
|
Chronic Lymphocytic Leukemia
CLL
|
venetoclax + ibrutinib
Sensitive: C3 – Early Trials
|
Chr del(17p)
Chr del(17p)
|
Chronic Lymphocytic Leukemia
CLL
|
obinutuzumab + zanubrutinib
Sensitive: C3 – Early Trials
|
Chr del(17p)
Chr del(17p)
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
obinutuzumab + zanubrutinib
Sensitive: C3 – Early Trials
|
Chr del(17p)
Chr del(17p)
|
Acute Myelogenous Leukemia
AML
|
MGD006
Sensitive: C3 – Early Trials
|
Chr del(17p)
Chr del(17p)
|
Multiple Myeloma
Multiple Myeloma
|
melphalan flufenamide
Sensitive: C3 – Early Trials
|
Chr del(17p)
Chr del(17p)
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
FCR
Sensitive: C3 – Early Trials
|
Chr del(17p)
Chr del(17p)
|
Chronic Lymphocytic Leukemia
CLL
|
FCR
Sensitive: C3 – Early Trials
|
Chr del(17p)
Chr del(17p)
|
Myelodysplastic Syndrome
MDS
|
azacitidine
Resistant: C3 – Early Trials
|
Chr del(17p)
Chr del(17p)
|
Multiple Myeloma
Multiple Myeloma
|
thalidomide
Resistant: C3 – Early Trials
|
Chr del(17p)
Chr del(17p)
|
Chronic Lymphocytic Leukemia
CLL
|
ibrutinib + UC-961
Sensitive: C3 – Early Trials
|
Chr del(17p)
Chr del(17p)
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
venetoclax + ibrutinib
Sensitive: C3 – Early Trials
|
Chr del(17p)
Chr del(17p)
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
ibrutinib + lisocabtagene maraleucel
Sensitive: C3 – Early Trials
|
Chr del(17p)
Chr del(17p)
|
Chronic Lymphocytic Leukemia
CLL
|
ibrutinib + lisocabtagene maraleucel
Sensitive: C3 – Early Trials
|
Chr del(17p)
Chr del(17p)
|
Multiple Myeloma
Multiple Myeloma
|
bortezomib
Sensitive: D – Preclinical
|
